{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:20:36Z","timestamp":1791922836372,"version":"4.3.4"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,4,28]]},"DOI":"10.1001\/jama.2020.3308","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T12:02:23Z","timestamp":1585310543000},"page":"1565","source":"Crossref","is-referenced-by-count":154,"title":["Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes"],"prefix":"10.1001","volume":"323","author":[{"given":"Kausik K.","family":"Ray","sequence":"first","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Buhr","sequence":"additional","affiliation":[{"name":"Statistical Data Analysis Center, University of Wisconsin\u2013Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Irving Institute for Clinical and Translational Research, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, University of California\u2013Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[{"name":"CGH Medical Center, Sterling, Illinois, and Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wong","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BETonMACE Investigators and Committees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6735","key":"joi200029r1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain.","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"issue":"1","key":"joi200029r2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0014-5793(01)03309-9","article-title":"Bromodomain: an acetyl-lysine binding domain.","volume":"513","author":"Zeng","year":"2002","journal-title":"FEBS Lett"},{"issue":"6","key":"joi200029r3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin.","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat Struct Mol Biol"},{"issue":"12","key":"joi200029r4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nsmb.2912","article-title":"BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones.","volume":"21","author":"Kanno","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"joi200029r5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-?B directs dynamic super enhancer formation in inflammation and atherogenesis.","volume":"56","author":"Brown","year":"2014","journal-title":"Mol Cell"},{"issue":"1","key":"joi200029r6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/biomedicines6010016","article-title":"BET family protein BRD4: an emerging actor in NF?B signaling in inflammation and cancer.","volume":"6","author":"Hajmirza","year":"2018","journal-title":"Biomedicines"},{"issue":"1","key":"joi200029r7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","article-title":"Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.","volume":"11","author":"Tsujikawa","year":"2019","journal-title":"Clin Epigenetics"},{"key":"joi200029r8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.dib.2016.07.047","article-title":"Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.","volume":"8","author":"Wasiak","year":"2016","journal-title":"Data Brief"},{"issue":"4","key":"joi200029r9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12265-017-9755-z","article-title":"Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208).","volume":"10","author":"Wasiak","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"key":"joi200029r10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","article-title":"RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease.","volume":"247","author":"Gilham","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"joi200029r11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2014.06.008","article-title":"A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.","volume":"236","author":"Jahagirdar","year":"2014","journal-title":"Atherosclerosis"},{"issue":"9","key":"joi200029r12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","article-title":"Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial.","volume":"57","author":"Nicholls","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"joi200029r13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","article-title":"Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial.","volume":"16","author":"Nicholls","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"joi200029r14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40256-018-0298-8","article-title":"The effect of bromodomain and extra-terminal inhibitor apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trial.","volume":"19","author":"Shishikura","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"joi200029r15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","article-title":"Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease.","volume":"18","author":"Nicholls","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"joi200029r16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ahj.2019.08.001","article-title":"Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: rationale, design, and baseline characteristics of the BETonMACE trial.","volume":"217","author":"Ray","year":"2019","journal-title":"Am Heart J"},{"issue":"7","key":"joi200029r17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/CIRCULATIONAHA.118.037202","article-title":"Frequency, regional variation, and predictors of undetermined cause of death in cardiometabolic clinical trials: a pooled analysis of 9259 deaths in 9 trials.","volume":"139","author":"Fanaroff","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"joi200029r18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"issue":"18","key":"joi200029r19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1161\/CIRCULATIONAHA.109.851873","article-title":"Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality.","volume":"120","author":"Tonelli","year":"2009","journal-title":"Circulation"},{"key":"joi200029r20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2019.09.002","article-title":"Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.","volume":"290","author":"Haarhaus","year":"2019","journal-title":"Atherosclerosis"},{"issue":"8","key":"joi200029r21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"joi200029r22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"joi200029r23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ Res"},{"issue":"22","key":"joi200029r24","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"joi200029r25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"joi200029r26","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"joi200029r27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2763951\/jama_ray_2020_oi_200029_1606935887.45871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T18:18:34Z","timestamp":1606933114000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2763951"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.3308","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}